Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Research & Development (2018 - 2025)

Neurogene (NGNE) has disclosed Research & Development for 5 consecutive years, with $17.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 5.87% year-over-year to $17.2 million, compared with a TTM value of $69.7 million through Sep 2025, up 36.51%, and an annual FY2024 reading of $60.9 million, up 37.22% over the prior year.
  • Research & Development was $17.2 million for Q3 2025 at Neurogene, down from $19.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $19.4 million in Q2 2025 and bottomed at $13.5 million in Q1 2024.